Cesca Therapeutics (KOOL) Reports Q3 Loss of $0.12, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Cesca Therapeutics Announces Third Quarter 2018 Financial Results And Provides Corporate Update
November 14, 2018 4:05 PM ESTRANCHO CORDOVA, Calif., Nov. 14, 2018 /PRNewswire/ -- Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced financial and operating results for the third quarter ended September 30, 2018 and provided a corporate update.
Third Quarter and Recent Highlights
Undertook additional cost-cutting measures in support of management's goal to become cash flow positive in 2019. Achieved third quarter 2018 net revenues of $3.1 million, up approximately 55% compared with $2.0 million in the second quarter of 2018 -- reflecting ongoing adoption and sales of... More